Homeopathic Drug Product Safety, Quality, and Transparency Act

The Homeopathic Drug Product Safety, Quality, and Transparency Act (HR 7050), introduced January 14, 2026, by Rep. Sessions (R-TX) with 3 cosponsors, has been referred to the House Committee on Energy and Commerce. At the earliest legislative stage, this bill imposes FDA pre-market approval requirements on homeopathic drug products, eliminating the current enforcement discretion policy that has allowed these products to reach market without individual FDA approval. The bill text establishes a distinct statutory pathway for homeopathic drugs but requires compliance with safety, quality, and transparency standards equivalent to new drug applications. The funding mechanism is zero — this is a regulatory bill, not an authorization or appropriation. The economic impact flows entirely through compliance costs: FDA New Drug Applications typically cost $500K to $2M per product, with clinical trial requirements for any therapeutic claims. The Congressional Budget Office would score this as reducing federal spending through reduced healthcare claims rather than direct appropriations. No executive orders amplify or conflict with this bill — the April 18, 2026 Executive Order on Accelerating Medical Treatments for Serious Mental Health concerns psychedelic therapies, a completely separate regulatory pathway. Structural losers are consumer health companies with homeopathic product lines. CHD is the most exposed, with Zicam (homeopathic nasal cold remedy) generating an estimated $80-100M annually — approximately 2% of CHD's $5.8B revenue. PG's Vicks homeopathic line (ZzzQuil, BabyRub) represents roughly 0.2% of their $84B revenue. CLX's RenewLife products are primarily probiotics rather than homeopathic dilution products, so impact depends on regulatory classification. No pure-play homeopathic companies trade on US public markets — the sector is dominated by privately held companies (Boiron, Hyland's, Nelsons) and divisions of larger CPG firms. Real market data as of April 28, 2026: CHD at $97.08 (52-week range $81.33-$106.04) with 7-day change of +4.5% and 30-day change of +2.52%. PG at $149.17 (52-week range $137.62-$170.99) with 7-day change of +4.42% and 30-day change of +4.53%. CLX at $96.60 (52-week range $95.73-$143.96) with 7-day change of -0.26% and 30-day change of -5.33%. Current price action shows no market pricing of this legislative risk — CHD and PG are near their 30-day highs, consistent with broader market strength in consumer staples, not reflecting homeopathic regulatory exposure. Timeline: This bill is at the earliest legislative stage — referred to committee with no hearings, markups, or floor votes scheduled. For the 119th Congress (2025-2027), the bill must pass through the Energy and Commerce Committee, House floor, Senate (similar bill or amendment), and Presidential signature. The pathway is long and uncertain — homeopathic regulation has been debated for over a decade without passage. If the bill advances, the primary market impact would be negative for affected tickers immediately upon committee mark-up or floor scheduling, not at current levels.